Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Operating Expenses (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Operating Expenses for 3 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 45.07% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.8 million through Dec 2025, down 13.91% year-over-year, with the annual reading at $40.8 million for FY2025, 13.91% down from the prior year.
  • Operating Expenses for Q4 2025 was $8.4 million at Mereo BioPharma, down from $10.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $15.3 million in Q4 2024, with the low at $6.4 million in Q2 2023.
  • Average Operating Expenses over 3 years is $10.3 million, with a median of $10.1 million recorded in 2024.
  • The sharpest move saw Operating Expenses surged 100.81% in 2024, then crashed 45.07% in 2025.
  • Over 3 years, Operating Expenses stood at $8.4 million in 2023, then surged by 81.82% to $15.3 million in 2024, then crashed by 45.07% to $8.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $8.4 million, $10.3 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.